# Alan Menter

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alan-menter/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,906 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 96 |
| i10-index | 307 |
| Last Known Institution | Baylor Medical Center at Garland |
| OpenAlex ID | https://openalex.org/A5075798284 |
| ORCID iD | https://orcid.org/0000-0002-9314-0007 |
| Works | 536 |

## Researcher papers

Showing 12 of 15.

- [Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways](https://scholariq.org/papers/genome-wide-scan-reveals-association-of-psoriasis-with-il-23-and-nf-b-pathways/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis/)
- [Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial](https://scholariq.org/papers/adalimumab-therapy-for-moderate-to-severe-psoriasis-a-randomized-controlled/)
- [Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis](https://scholariq.org/papers/comparison-of-ustekinumab-and-etanercept-for-moderate-to-severe-psoriasis/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [European S3‐Guidelines on the systemic treatment of psoriasis vulgaris](https://scholariq.org/papers/european-s3-guidelines-on-the-systemic-treatment-of-psoriasis-vulgaris/)
- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci](https://scholariq.org/papers/a-genome-wide-association-study-of-psoriasis-and-psoriatic-arthritis-identifies/)
- [Guidelines of care for the management of psoriasis and psoriatic arthritis](https://scholariq.org/papers/guidelines-of-care-for-the-management-of-psoriasis-and-psoriatic-arthritis/)
- [Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis-2/)
- [Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies](https://scholariq.org/papers/joint-american-academy-of-dermatology-national-psoriasis-foundation-guidelines/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [Baylor Medical Center at Garland](https://scholariq.org/institutions/baylor-medical-center-at-garland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.